Clinical trial NCT02581488: Use of Santyl in Diabetic Foot Ulcers
Official title: Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetic Foot
Foot Ulcer, Diabetic
Keywords: Diabetes
diabetic foot ulcer
foot sore
type 2 diabetes
type 1 diabetes
neuropathy
DFU
Lead sponsor: Smith & Nephew, Inc.
Sponsor class: INDUSTRY
First posted: 2015-10-21
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers treated with a topical treatment containing silver. After meeting study criteria, participants will be randomly assigned to apply SANTYL or a topical treatment containing silver to their to foot ulcer for up to 6 weeks. At the end of 6 weeks, participants will be followed for an additional 4 weeks to examine the outcome of the study treatment.

Detailed description: The objectives of this study were to compare outcomes of diabetic foot ulcers (DFUs) treated with SANTYL or silver-containing products, both in combination with sharp debridement as needed. One hundred two subjects with qualifying DFUs were randomized to daily treatment with either SANTYL or a silver-containing product for 6 weeks followed by a 4 -week follow-up period. The primary outcome was the mean percent reduction in DFU area. A secondary outcome was the incidence of ulcer infections between groups.

Eligibility criteria: Inclusion Criteria:

1. Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
2. Eighteen (18) years of age or older, of either sex, and of any race or skin type.
3. Willing and able to make all required study visits.
4. Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.
5. Willing to use an appropriate off-loading device to keep weight off of foot ulcers.
6. An ulcer present on any part of the plantar surface of the neuropathic foot or hallux which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit using the ARANZ Silhouette imaging device). The target ulcer duration must be ≥ 6 weeks but not more than 52 weeks (12 months) as documented in the subject's history or by subject report of onset, and which requires debridement.
7. Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of \> 0.70 and ≤ 1.20. If ABI \> 1.2, perfusion at or near the site of the ulcer should be confirmed; the foot is warm to the touch and has palpable pulses.
8. Separation of at least 5 cm (closest ulcer edge to other closest ulcer edge) if ≥ 2 ulcers are present as measured using the ARANZ Silhouette imaging device.
9. Diabetes mellitus (Type 1 or 2) requiring insulin or oral/injectable medications to control blood glucose levels.
10. Target ulcer is not infected based on clinical assessment.

Exclusion Criteria:

1. Contraindications or hypersensitivity to the use of clostridial collagenase or products containing silver.
2. Participation in another clinical trial within thirty (30) days of Visit 1, or planned participation overlapping with this study.
3. Bleeding disorder that would preclude sharp debridement during the study.
4. Active cellulitis of the target ulcer, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
5. Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).
6. A target ulcer which involves the underlying tissues of tendon, muscle, or bone.
7. Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.
8. Current treatment (at the time of the Screening Visit) with any of the following:

   * Systemic corticosteroids. If corticosteroid treatment was for ≥ 10 days, there must be a 1 week interval between discontinuation and screening.
   * Immunosuppressive agents
   * Chemotherapeutic agents
   * Antiviral agents
   * Systemic antibiotic therapy (for any reason) or topical antibiotic treatment of the target ulcer
9. Treatment of target ulcer with bioactive therapies within 1 month of screening:

   * Platelet-derived growth factor (e.g., Regranex®)
   * Living skin equivalent (e.g., Apligraf®)
   * Dermal substitute (e.g., Dermagraft®, Integra®, Oasis®, etc.)
   * Amniotic membrane products (e.g., EpiFix®, Grafix®, etc.)
10. Prior treatment of target ulcer for any length of time with clostridial collagenase ointment (SANTYL®).
11. Radiation therapy to the target lower extremity within 30 days prior to screening.
12. Medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
13. Blood counts and blood chemistry values as follows:

    * Alanine aminotransferase (ALT) \> 3x upper limit of normal
    * Aspartate aminotransferase (AST) \> 3x upper limit of normal
    * Gamma Glutamyl Transferase (GGT) \> 2.5x upper limit of normal
    * Serum albumin \< 2.0 g/dL • Pre-albumin levels of \< 10 mg/dL
    * Alkaline phosphatase \> 500 U/L • Serum total bilirubin \> 3.0 mg/dL
    * Serum BUN \> 75 mg/dL • Serum creatinine \> 4.5 mg/dL
    * HbA1c \> 12% • Hemoglobin (Hgb) \< 8.0 g/dL
    * WBC \< 2.0 x 109/L • Absolute neutrophil count \< 1.0 x 109/L
    * Platelet count \< 50 x 109/L

Primary outcomes:
measure: Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment.
timeFrame: 6 weeks
Secondary outcomes:
measure: Target Ulcer Infection Rates in Each Treatment Group During the Treatment Period as Determined by Investigator-reported Adverse Events
timeFrame: 6 weeks
Other outcomes:
measure: Time to Closure for Ulcers Achieving Closure in Treatment Period
timeFrame: 6 weeks
measure: Time to Closure for Ulcers Achieving Closure by End of Follow-up
timeFrame: 10 weeks
Locations:
city: Sylmar
country: United States
state: California
city: Melbourne
country: United States
state: Florida
city: Baltimore
country: United States
state: Maryland
city: Las Vegas
country: United States
state: Nevada
city: York
country: United States
state: Pennsylvania
city: Fort Worth
country: United States
state: Texas
city: McAllen
country: United States
state: Texas
city: Saint George
country: United States
state: Utah
city: Harrisonburg
country: United States
state: Virginia
city: Roanoke
country: United States
state: Virginia
city: Virginia Beach
country: United States
state: Virginia
city: Hamilton
country: Canada
state: Ontario
city: Boucherville
country: Canada
state: Quebec
Study officials:
affiliation: Smith & Nephew, Inc.
name: Robert Eichelkraut
role: STUDY_CHAIR
References: